Merck presented data Monday showing its Vytorin cholesterol treatment performing well in several studies.

Merck ( MRK) released a new analysis of three studies that it says shows Vytorin reduced LDL, or "bad," cholesterol by an average of 52.5% in patients with high cholesterol. The company said the same analysis found its other cholesterol drug, Zocor, showed an average reduction of 38%.

Merck's analysis pooled data from three similar randomized studies that included a total of 3,083 patients with primary hypercholesterolemia. The study also measured a risk factor for cardiovascular disease called "C-reactive protein," or CRP.

A pooled analysis across all doses of Vytorin and Zocor found geometric mean CRP levels declined in patients taking Vytorin by 31% as compared to a 14.3% reduction in the group of patients taking Zocor.

The results were presented Monday at the 55th Annual Scientific Session of the American College of Cardiology.

More from Stocks

Dow Gets Swept Into Nasty Reversal Even as Nasdaq Posts New Record

Dow Gets Swept Into Nasty Reversal Even as Nasdaq Posts New Record

REPLAY: Jim Cramer on Fed Rate Hikes, Oil Prices and Starbucks Worries

REPLAY: Jim Cramer on Fed Rate Hikes, Oil Prices and Starbucks Worries

What Will GM Do With Cruise -- and Is Its Stock Worth $55?

What Will GM Do With Cruise -- and Is Its Stock Worth $55?

3 Must Reads on the Market From TheStreet's Top Columnists

3 Must Reads on the Market From TheStreet's Top Columnists

This Should Be Your Retirement Savings Plan When the Stock Market Crashes

This Should Be Your Retirement Savings Plan When the Stock Market Crashes